OptimizeRx Corp. reported first-quarter 2025 net revenue of $21.9 million, an 11% increase year-over-year, surpassing both consensus estimates and internal expectations. The company demonstrated strong top-line growth.
The net loss for Q1 2025 significantly reduced to $2.2 million, a substantial improvement from the $6.9 million loss in the prior-year period. Adjusted EBITDA for the quarter reached $1.5 million, representing a nearly $2 million improvement year-over-year.
Based on this strong performance, OptimizeRx raised its full-year 2025 guidance, now expecting revenue between $101 million and $106 million and Adjusted EBITDA between $13 million and $15 million. The company also noted that over 5% of its expected 2025 sales have already converted to subscription-based revenue streams.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.